These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 22666217)

  • 1. Emerging targeted therapies for castration-resistant prostate cancer.
    Adamo V; Noto L; Franchina T; Chiofalo G; Picciotto M; Toscano G; Caristi N
    Front Endocrinol (Lausanne); 2012; 3():73. PubMed ID: 22666217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The treatment of castration-resistant prostate cancer].
    Petrányi Á
    Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging treatment options for patients with castration-resistant prostate cancer.
    George D; Moul JW
    Prostate; 2012 Feb; 72(3):338-49. PubMed ID: 21748753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New and emerging agents for the treatment of castration-resistant prostate cancer.
    Higano CS; Crawford ED
    Urol Oncol; 2011; 29(6 Suppl):S1-8. PubMed ID: 22074657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New developments in castrate-resistant prostate cancer.
    Shore N; Mason M; de Reijke TM
    BJU Int; 2012 Jun; 109 Suppl 6():22-32. PubMed ID: 22672122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
    Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New agents for prostate cancer.
    Agarwal N; Di Lorenzo G; Sonpavde G; Bellmunt J
    Ann Oncol; 2014 Sep; 25(9):1700-1709. PubMed ID: 24658665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging novel therapies for advanced prostate cancer.
    Osanto S; Van Poppel H
    Ther Adv Urol; 2012 Feb; 4(1):3-12. PubMed ID: 22295041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging novel therapies in the treatment of castrate-resistant prostate cancer.
    Abdulla A; Kapoor A
    Can Urol Assoc J; 2011 Apr; 5(2):120-33. PubMed ID: 21470540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel molecular targets for the therapy of castration-resistant prostate cancer.
    Agarwal N; Sonpavde G; Sternberg CN
    Eur Urol; 2012 May; 61(5):950-60. PubMed ID: 22209376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
    Payne H; Bahl A; Mason M; Troup J; De Bono J
    BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Castration-resistant prostate cancer: latest evidence and therapeutic implications.
    Suzman DL; Antonarakis ES
    Ther Adv Med Oncol; 2014 Jul; 6(4):167-79. PubMed ID: 25057303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel options for the treatment of castration-resistant prostate cancer.
    Ohlmann CH; Merseburger AS; Suttmann H; Schilling D; Trojan L; Kempkensteffen C; Corvin S; Mathers MJ; Bastian PJ
    World J Urol; 2012 Aug; 30(4):495-503. PubMed ID: 22101903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New therapies in metastatic castration resistant prostate cancer].
    Thibault C; Massard C
    Bull Cancer; 2015 Jun; 102(6):501-8. PubMed ID: 26022286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Castration resistant prostate cancer (CRPC): state of the art, perspectives and new challenges.
    Massari F; Maines F; Modena A; Brunelli M; Bria E; Artibani W; Martignoni G; Tortora G
    Anticancer Agents Med Chem; 2013 Jul; 13(6):872-86. PubMed ID: 23272970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of metastatic castration-resistant prostate cancer.
    Antonarakis ES
    Eur Urol Rev; 2011; 6(2):90-96. PubMed ID: 23789039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel and bone-targeted agents for CRPC.
    Fizazi K; Albiges L; Massard C; Escudier B; Loriot Y
    Ann Oncol; 2012 Sep; 23 Suppl 10():x264-7. PubMed ID: 22987974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment options in castration-resistant prostate cancer: current therapies and emerging docetaxel-based regimens.
    Saad F; Miller K
    Urol Oncol; 2014 Feb; 32(2):70-9. PubMed ID: 23506965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.